Immunovant, Inc. Common Stock (IMVT) is a publicly traded Healthcare sector company. As of September 23, 2026, IMVT trades at $34.61 with a market cap of $7.68B and a P/E ratio of -13.39. IMVT moved -7.20% today. Year to date, IMVT is +46.70%; over the trailing twelve months it is +139.19%. Its 52-week range spans $12.72 to $45.42. Analyst consensus is strong buy with an average price target of $49.70. Rallies surfaces IMVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for IMVT, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $34.61 |
| Market Cap | $7.68B |
| P/E Ratio | -13.39 |
| EPS | $-2.77 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.42 |
| 52-Week Low | $12.72 |
| Volume | 119.78K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-505.61M |
| Gross Margin | 0.00% |
10 analysts cover IMVT: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.70.